Current Rheumatology Reports

, Volume 6, Issue 2, pp 156–163 | Cite as

Antibodies in scleroderma: Direct pathogenicity and phenotypic associations

  • Lorinda Chung
  • Paul J. Utz


Scleroderma is an autoimmune disease involving endothelial cell damage and fibroblast overproduction of extracellular matrix. Several autoantibodies present in the sera of patients with scleroderma, including anti-endothelial cell, antifibroblast, anti-matrix metalloproteinase, and antifibrillin-1 antibodies, may directly contribute to disease pathogenesis. Scleroderma also is characterized by the presence of antinuclear and antinucleolar antibodies, which correlate with particular phenotypes. These include antitopoisomerase-I, anticentromere, antihistone, anti-polymyositis/ scleroderma, anti-Th/To, anti-U3-small nucleolar ribonucleoprotein particle, anti-U1-small nuclear ribonucleoprotein particle, anti-RNA polymerase, and anti-B23 antibodies. Other antibodies classically associated with other autoimmune diseases, such as antiphospholipid, antineutrophil cytoplasmic, and antimitochondrial antibodies, also have been described in patients with scleroderma. This review will summarize the various autoantibodies associated with scleroderma, their putative pathogenic roles, and their phenotypic correlations.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pope JE: Scleroderma overlap syndromes. Curr Opin Rheumatol 2002, 14:704–710.PubMedCrossRefGoogle Scholar
  2. 2.
    Zhou X, Tan FK, Xiong M, et al.: Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001, 167:7126–7133.PubMedGoogle Scholar
  3. 3.
    Harris ML, Rosen A: Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003, 15:778–784. This review highlights novel autoantibodies and novel phenotypic associations, as well as the potential role of autoantibodies in scleroderma.PubMedCrossRefGoogle Scholar
  4. 4.
    Sato S, Hasegawa M, Fujimoto M, et al.: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635–6643.PubMedGoogle Scholar
  5. 5.
    Wigley FM: Systemic sclerosis: clinical features. In Primer on the Rheumatic Diseases. Edited by Klippel JH. Atlanta: Arthritis Foundation; 2001:357–364.Google Scholar
  6. 6.
    Worda M, Sgonc R, Dietrich H, et al.: In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum 2003, 48:2605–2614.PubMedCrossRefGoogle Scholar
  7. 7.
    Negi VS, Tripathy NK, Misra R, et al.: Anti-endothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998, 25:462–466.PubMedGoogle Scholar
  8. 8.
    Chizzolini C, Raschi E, Rezzonico R, et al.: Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002, 46:1602–1613.PubMedCrossRefGoogle Scholar
  9. 9.
    Sato S, Hayakawa I, Hasegawa M, et al.: Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003, 120:542–547.PubMedCrossRefGoogle Scholar
  10. 10.
    Saito E, Fujimoto M, Hasegawa M, et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453–1462.PubMedCrossRefGoogle Scholar
  11. 11.
    Tan FK, Arnett FC, Reveille JD, et al.: Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000, 43:2464–2471.PubMedCrossRefGoogle Scholar
  12. 12.
    Wallis DD, Tan FK, Kielty CM, et al.: Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001, 44:1855–1864.PubMedCrossRefGoogle Scholar
  13. 13.
    Hu PQ, Fertig N, Medsger TA, et al.: Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 2003, 48:1363–1373. These researchers used a highly sensitive enzyme-linked immunosorbent assay to study anti-topo-I titers in 59 patients with diffuse scleroderma. They showed that titers of anti-topo-I IgG and IgA correlated with the total skin score and disease activity in patients with scleroderma.PubMedCrossRefGoogle Scholar
  14. 14.
    Hesselstrand R, Scheja A, Shen GQ, et al.: The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003, 42:534–540.PubMedCrossRefGoogle Scholar
  15. 15.
    Reveille JD, Solomon DH: Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399–412. This review summarizes the sensitivity and specificity of various assays for autoantibodies associated with scleroderma. The authors provide guidelines for the use of autoantibody testing in clinical practice.PubMedCrossRefGoogle Scholar
  16. 16.
    Schachna L, Wigley FM, Morris S, et al.: Recognition of granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum 2002, 46:1873–1884. This paper emphasizes the importance of modification of autoantigens in the immune response of patients with scleroderma. The authors showed that ACAs target modified centromere proteins in a subset of limited scleroderma patients with ischemic digital loss.PubMedCrossRefGoogle Scholar
  17. 17.
    van Eenennaam H, Vogelzangs JHP, Bisschops L, et al.: Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002, 130:532–540.PubMedCrossRefGoogle Scholar
  18. 18.
    Ulanet DB, Wigley FM, Gelber AC, et al.: Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 2003, 49:85–92.PubMedCrossRefGoogle Scholar
  19. 19.
    Brouwer R, Pruijn GJM, van Venrooij WJ: The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Research 2001, 3:102–106.PubMedCrossRefGoogle Scholar
  20. 20.
    Brouwer R, Vree Egberts WTM, Hengstman GJD, et al.: Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Res 2002, 4:134–138.PubMedCrossRefGoogle Scholar
  21. 21.
    van Eenennaam H, Vogelzangs JHP, Lugtenberg D, et al.: Identity of the RNase MRP- and RNase P-associated Th/To autoantigen. Arthritis Rheum 2002, 46:3266–3272.PubMedCrossRefGoogle Scholar
  22. 22.
    Mitri GM, Lucas M, Fertig N et al.: A comparison between anti- Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003, 48:203–209. These authors compared patients with limited scleroderma who were ACA-positive to those who were anti-Th/To antibody-positive. Patients with anti-Th/To antibodies were found to have certain features more frequently associated with diffuse scleroderma, including pulmonary fibrosis and renal crisis.PubMedCrossRefGoogle Scholar
  23. 23.
    Okano Y, Medsger TA: Antibody to Th ribonucleoprotein (nucleolar 7–2 RNA protein particle) in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1990, 33:1822–1828.PubMedCrossRefGoogle Scholar
  24. 24.
    Kuwana M, Kimura K, Hirakata M, et al.: Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 2002, 61:842–846.PubMedCrossRefGoogle Scholar
  25. 25.
    Yang JM, Hildebrandt B, Luderschmidt C, et al.: Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum 2003, 48:210–217.PubMedCrossRefGoogle Scholar
  26. 26.
    Arnett FC, Reveille JD, Goldstein R, et al.: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151–1166.PubMedCrossRefGoogle Scholar
  27. 27.
    Steen V, Medsger TA: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003, 48:516–522.PubMedCrossRefGoogle Scholar
  28. 28.
    Burdt MA, Hoffman RW, Deutscher SL, et al.: Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999, 42:899–909.PubMedCrossRefGoogle Scholar
  29. 29.
    Greidinger EL, Casciola-Rosen L, Morris SM, et al.: Autoantibody recognition of distinctly modified forms of the U1-70- kd antigen is associated with different clinical disease manifestations. Arthritis Rheum 2000, 43:881–888.PubMedCrossRefGoogle Scholar
  30. 30.
    Asano Y, Ihn H, Yamane K, et al.: The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 2003, 120:204–210.PubMedCrossRefGoogle Scholar
  31. 31.
    Harvey GR, Butts S, Rands AL, et al.: Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999, 117:395–402.PubMedCrossRefGoogle Scholar
  32. 32.
    Kuwana M, Kimura K, Kawakami Y: Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera. Arthritis Rheum 2002, 46:2742–2747.PubMedCrossRefGoogle Scholar
  33. 33.
    Schoenroth L, Fritzler M, Lonzetti L, et al.: Antibodies to [beta]2 glycoprotein I and cardiolipin in SSc. Ann Rheum Dis 2002, 61:183–184.PubMedCrossRefGoogle Scholar
  34. 34.
    Ihn H, Sato S, Fujimoto M, et al.: Measurement of anticardiolipin antibodies by ELISA using beta 2-glycoprotein I (beta 2-GPI) in systemic sclerosis. Clin Exp Immunol 1996, 105:475–479.PubMedCrossRefGoogle Scholar
  35. 35.
    Pope JE, Thompson A: The frequency and significance of anticardiolipin antibodies in scleroderma. J Rheumatol 2000, 27:1450–1452.PubMedGoogle Scholar
  36. 36.
    Antonioli CM, Danieli E, Airo P, et al.: More on anticardiolipin and anti-beta 2 glycoprotein I in systemic sclerosis. Ann Rheum Dis 2003, 62:589–590.PubMedCrossRefGoogle Scholar
  37. 37.
    Endo H, Hosono T, Kondo H: Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 1994, 21:864–870.PubMedGoogle Scholar
  38. 38.
    Wutzl AL, Foley RN, O’Driscoll BR, et al.: Microscopic polyangiitis presenting as pulmonary-renal syndrome in a patient with long-standing diffuse cutaneous systemic sclerosis and antibodies to myeloperoxidase. Arthritis Care Res 2001, 45:533–536.CrossRefGoogle Scholar
  39. 39.
    Miyata N, Kobayashi T, Matsukawa Y, et al.: Anti-neutrophil cytoplasmic autoantibody-associated rapid progressive glomerulonephritis complicated with both limited and diffuse scleroderma. Nihon Rinsho Meneki Gakkai Kaishi 2002, 25:473–479.PubMedGoogle Scholar
  40. 40.
    Casari S, Haeney M, Farrand S, et al.: Antineutrophil cytoplasmic antibodies: a "red flag" in patients with systemic sclerosis. J Rheumatol 2002, 29:2666–2667.PubMedGoogle Scholar
  41. 41.
    Khanna D, Aggarwal A, Bhakuni DS, et al.: Bactericidal/permeability- increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J Rheumatol 2003, 30:1248–1252.PubMedGoogle Scholar
  42. 42.
    Fregeau DR, Leung PSC, Coppel RL, et al.: Autoantibodies to mitochondria in systemic sclerosis: frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum 1988, 31:386–392.PubMedCrossRefGoogle Scholar
  43. 43.
    Tojo J, Ohira H, Suzuki T, et al.: Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. Hepatol Res 2002, 22:187–195.PubMedCrossRefGoogle Scholar
  44. 44.
    Whyte J, Hough D, Maddison PJ, et al.: The association of primary biliary cirrhosis and systemic sclerosis is not accounted for by cross reactivity between mitochondrial and centromere antigens. J Autoimmun 1994, 7:413–424.PubMedCrossRefGoogle Scholar
  45. 45.
    Katsumata Y, Suzuki T, Kuwana M, et al.: Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis. Arthritis Rheum 2003, 48:1647–1651.PubMedCrossRefGoogle Scholar
  46. 46.
    Griffith KJ, Ryan JP, Senecal J-L, et al.: The cytoplasmic linker protein CLIP-170 is a human autoantigen. Clin Exp Immunol 2002, 127:533–538.PubMedCrossRefGoogle Scholar
  47. 47.
    Berger T, Rubner P, Schautzer F, et al.: Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003, 349:139–145.PubMedCrossRefGoogle Scholar
  48. 48.
    Arbuckle MR, McClain MT, Rubertone MV, et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526–1533. This study demonstrates the predictable appearance of autoantibodies before the diagnosis of SLE, emphasizing the probable pathogenic role of certain autoantibodies in autoimmune diseases.PubMedCrossRefGoogle Scholar
  49. 49.
    Rantapaa-Dahlqvist S, de Jong BAW, Berglin E, et al.: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741–2749.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Lorinda Chung
    • 1
  • Paul J. Utz
  1. 1.Division of Immunology and Rheumatology, Department of MedicineStanford University School of MedicineStanfordUSA

Personalised recommendations